Satellite Meetings at RSNA for Providers Interested in TMIST
Large-scale breast cancer screening trial will compare tomosynthesis and digital mammography.
The Tomosynthesis Mammography Imaging Screening Trial (TMIST) by the ECOG-AGRIN Cancer Research Group is now recruiting medical facilities with an estimated open trial date of mid 2017.
The first large-scale breast cancer screening trial in nearly 25 years has been approved for funding by the National Cancer Institute and will enroll 165,000 asymptomatic women in the U.S. and Canada between ages 45 and 74. The trial is aimed at comparing the incidence of advanced cancers in those screened for four years with digital breast tomosynthesis vs. standard digital mammography.
TMIST will require nearly 100 sites with an estimated four to five women per day to reach the accrual goal in three years, according to a release.
Participation eligibility includes:
• U.S.- or Canada-based medical facility
• Able to provide digital breast tomosynthesis and standard digital mammography in the same location
• Member of a research group in the NCI National Clinical Trials Network (NCTN) either directly or through the NCI Community Oncology Research Program (NCORP)
Interested medical providers can attend one of two available TMIST information sessions at RSNA 2016:
TMIST Satellite Session One
Monday, Nov. 28, 1:30-2:30 in McCormick Place – W470a
TMIST Satellite Session Two
Wednesday, Nov. 30, 11:00-12:00 in McCormick Place – W192b
Preregistration is not required.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
